Status:

COMPLETED

Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)

Lead Sponsor:

Menarini Group

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.

Detailed Description

Irritable Bowel Syndrome (IBS) is a functional disorder characterised by chronic or recurrent abdominal pain or discomfort associated with altered bowel habits. This trial aims to evaluate the efficac...

Eligibility Criteria

Inclusion

  • Male or female patients aged 18 - 70 years.
  • Clinical diagnosis of IBS .
  • For patients older than 50 years or patients with positive family history of colorectal cancer: normal results from colonoscopy or flexible sigmoidoscopy.
  • Use of appropriate contraceptive methods.
  • Normal physical examination or without clinically relevant abnormalities.

Exclusion

  • Patients with organic abnormalities of the gastro-intestinal tract including history of colonic or major abdominal surgery, current or previous diagnosis of neoplasia, inflammatory bowel diseases, symptomatic gallbladder stone disease, diverticulosis/diverticulitis, ectopic endometriosis.
  • History of gluten enteropathy.
  • Lactose intolerance as assessed by response to diet
  • Diagnosis of ova or parasites, or occult blood in the stool in the previous 6 months.
  • Previous diagnosis of Diabetes Mellitus (either type 1 or 2)
  • Unstable medical condition.
  • Concomitant medication within 7 days prior to screening with drugs known to interfere with gastro-intestinal motility and sensitivity.
  • Pregnancy or breastfeeding.
  • Patient not able to understand or collaborate throughout the study.
  • Participation in other clinical trials in the previous 4 weeks.

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

554 Patients enrolled

Trial Details

Trial ID

NCT00761007

Start Date

July 1 2008

End Date

March 1 2009

Last Update

March 21 2012

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Center for Clinical and Basic Research (CCBR)

Ballerup Municipality, Denmark

2

emovis GmbH

Berlin, Germany

3

Digestive Diseases Center "Gastro"

Riga, Latvia

4

Federal State Institution "Outpatient clinic #3" of President's Management Department of the Russian Federation

Moscow, Russia

Ibodutant for Relief of Irritable Bowel Syndrome (IRIS) | DecenTrialz